MedTrace Logo

A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer

NCT03193541 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2026-02-04

No results posted yet for this study

Summary

To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with microscopic hematuria.

Conditions

Sponsors & Collaborators

  • Nonagen Bioscience Corporation

    collaborator INDUSTRY

  • Nara Medical University

    collaborator OTHER

  • University of California, Los Angeles

    collaborator OTHER

  • University of Rochester

    collaborator OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Texas, Southwestern Medical Center at Dallas

    collaborator OTHER

  • VA Long Beach Healthcare System

    collaborator FED

  • Nara Prefecture Seiwa Medical Center

    collaborator UNKNOWN

  • University of Hawaii Cancer Research Center

    collaborator OTHER

  • Fred Hutchinson Cancer Center

    collaborator OTHER

  • Hoag Memorial Hospital Presbyterian

    collaborator OTHER

  • Cedars-Sinai Medical Center

    lead OTHER

Principal Investigators

  • Charles Rosser, MD · Nonagen Bioscience Corporation

  • Hideki Furuya, PhD · Cedars-Sinai Medical Center

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-30
Primary Completion
2029-02-28
Completion
2029-02-28

Countries

  • United States
  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03193541 on ClinicalTrials.gov